Blog
RSS FeedPosted by Michael Wonder on 15 Feb 2024
Japan’s FY 2024 pricing reform expected to favour new listed innovative drugs
15 February 2024 - To address and maintain the financial sustainability of the national insurance system, the Government rolled out several ...
Posted by Michael Wonder on 15 Feb 2024
Launch of new HMA-EMA catalogues of real world data sources and studies
15 February 2024 - The EMA and the Heads of Medicines Agencies have launched two public electronic catalogues: one for ...
Posted by Michael Wonder on 13 Feb 2024
Federal judge tosses PhRMA lawsuit challenging Medicare drug negotiations
12 February 2024 - A Texas federal judge on Monday dismissed a lawsuit challenging the Biden administration’s Medicare drug price ...
Posted by Michael Wonder on 12 Feb 2024
House of Representatives passes bill to ban use of QALYs in federally funded health care programs
12 February 2024 - The U.S. House of Representatives passed H.R. 485, the Protecting Health Care for All Patients Act, this ...
Posted by Michael Wonder on 08 Feb 2024
In a showy hearing, Bernie Sanders gets few answers about lower drug prices
8 February 2024 - Call it Senator Bernie Sanders’ prescription drug pricing theater. ...
Posted by Michael Wonder on 08 Feb 2024
J&J, Merck and Bristol Myers CEOs defend high drug prices in Senate hearing, as Biden tries to cut costs
8 February 2024 - The CEOs of Johnson & Johnson, Merck and Bristol Myers Squibb defended high drug prices in the ...
Posted by Michael Wonder on 01 Feb 2024
Biden-Harris Administration to make first offer for drug price negotiation program, launches new resource hub to help people access lower cost drugs
1 February 2024 - Department of Human and Health Services also releases new research showing that the United States pays ...
Posted by Michael Wonder on 30 Jan 2024
Pharma price cut proposals from US Government could be steep, analysts say
29 January 2024 - Pharmaceutical companies are due to receive by Thursday the US Government's opening proposal for what are ...
Posted by Michael Wonder on 29 Jan 2024
Will Medicare push drug prices down in 2024?
29 January 2024 - Medicare participants will get insight this year into how much the prices of certain drugs will ...
Posted by Michael Wonder on 29 Jan 2024
Merck, Johnson & Johnson CEOs agree to testify in Senate hearing on high drug prices
26 January 2024 - Bristol Myers Squibb CEO Chris Boerner and another unnamed pharmaceutical CEO accepted initial invitations to testify. ...
Posted by Michael Wonder on 26 Jan 2024
CHMP issues negative opinion for renewal of conditional marketing authorisation for Translarna (ataluren) following re-examination procedure
25 January 2024 - PTC Therapeutics announced today that the CHMP of the EMA issued a negative opinion following the re-examination ...
Posted by Michael Wonder on 24 Jan 2024
FDA's ISTAND Pilot Program accepts submission of first artificial intelligence based and digital health technology for neuroscience
23 January 2024 - FDA's Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research recently accepted a ...
Posted by Michael Wonder on 24 Jan 2024
US FDA seeks 'boxed warning' for CAR-T cancer therapies
22 January 2024 - The US health regulator on Monday asked a host of drug makers, including Gilead Sciences, Johnson ...
Posted by Michael Wonder on 23 Jan 2024
Lower drug costs are just a federal license away. But they require Biden Administration leadership.
23 January 2024 - It’s a longstanding Government failure to never use federal “march-in” licensing rights to lower drug prices. It’s ...
Posted by Michael Wonder on 22 Jan 2024
In ‘march-in’ rights, some see a tool to lower drug prices. Others see a threat to intellectual property.
22 January 2024 - In the fall of 2020, Robert Sachs was prescribed a medication to treat prostate cancer that had ...